Identify drugs in commercial use or in ongoing clinical development that can immediately initiate a phase II/III clinical trial for COVID-19.

Effective SARS-CoV-2 drugs will be identified from chemical libraries of compounds (collections of chemical compounds) approved by international drug regulatory and marketing authorization agencies (such as the FDA in the USA or the EMA in the EU). It will be carried out using chemo-informatic techniques (virtual screening, knowledge about the infection and about the chemical structure of drugs currently in use in COVID-19 patients).

Phases II and III of the clinical trial refer to checking whether II: the treatment is effective, in other words, whether it works; and III: whether the new treatment under study is better than the conventional treatment. 

Principal Investigator: Carmen Gil (CIB)

We use cookies on this site to improve your user experience. More info. ACEPTAR

Aviso de cookies